[{"orgOrder":0,"company":"KeyBioscience","sponsor":"Eli Lilly","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"SWITZERLAND","productType":"Other Large Molecule","year":"2024","type":"Expanded Collaboration","leadProduct":"LY3541105","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"KeyBioscience","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"KeyBioscience \/ Eli Lilly","highestDevelopmentStatusID":"6","companyTruncated":"KeyBioscience \/ Eli Lilly"}]

Find Clinical Drug Pipeline Developments & Deals by KeyBioscience

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          IMCAS Asia
                          Not Confirmed
                          IMCAS Asia
                          Not Confirmed

                          Details : Lilly will receive worldwide rights to develop and commercialize Dual Amylin Calcitonin Receptor Agonists (DACRA), a new class of potential treatments for obesity and related disorders.

                          Product Name : LY3541105

                          Product Type : Other Large Molecule

                          Upfront Cash : Undisclosed

                          October 10, 2024

                          Lead Product(s) : LY3541105

                          Therapeutic Area : Nutrition and Weight Loss

                          Highest Development Status : Phase I

                          Sponsor : Eli Lilly

                          Deal Size : $1,400.0 million

                          Deal Type : Expanded Collaboration

                          blank